Mediclinic International plc (MDC) is a leading medical care facilities business based in the UK. It opened the day at 270p after a previous close of 270.6p. During the day the price has varied from a low of 261.2p to a high of 270p. The latest price was 265.8p (25 minute delay). Mediclinic International is listed on the London Stock Exchange (LSE) and employs 34,262 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Mediclinic International's share price has had significant negative movement.
Its last market close was 267p, which is 31.56% down on its pre-crash value of 390.1p and 7.32% up on the lowest point reached during the March crash when the shares fell as low as 248.8p.
If you had bought £1,000 worth of Mediclinic International shares at the start of February 2020, those shares would have been worth £724.75 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £713.53.
|52-week range||232.4p - 419.4p|
|50-day moving average||263.4743p|
|200-day moving average||269.7879p|
|Wall St. target price||448p|
|Dividend yield||0.08p (2.96%)|
|Earnings per share (TTM)||17.1p|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|3 months (2020-06-24)||4.73%|
|6 months (2020-03-24)||-8.97%|
Valuing Mediclinic International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mediclinic International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mediclinic International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Mediclinic International shares trade at around 23x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Mediclinic International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £479 million.
The EBITDA is a measure of a Mediclinic International's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£3.1 billion|
|Operating margin TTM||10.51%|
|Gross profit TTM||£1.1 billion|
|Return on assets TTM||3.03%|
|Return on equity TTM||-9.54%|
|Market capitalisation||£2 billion|
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Mediclinic International.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 22.08
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Mediclinic International's overall score of 22.08 (as at 08/01/2020) is pretty good – landing it in it in the 34th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Mediclinic International is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.69/100
Mediclinic International's environmental score of 0.69 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Mediclinic International is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 11.99/100
Mediclinic International's social score of 11.99 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Mediclinic International is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.4/100
Mediclinic International's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Mediclinic International is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Mediclinic International scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Mediclinic International has, for the most part, managed to keep its nose clean.
|Total ESG score||22.08|
|Total ESG percentile||33.62|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
Dividend payout ratio: 46.2% of net profits
Recently Mediclinic International has paid out, on average, around 46.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.96% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Mediclinic International shareholders could enjoy a 2.96% return on their shares, in the form of dividend payments. In Mediclinic International's case, that would currently equate to about 0.08p per share.
While Mediclinic International's payout ratio might seem fairly standard, it's worth remembering that Mediclinic International may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 5 December 2019 (the "ex-dividend date").
Over the last 12 months, Mediclinic International's shares have ranged in value from as little as 232.4p up to 419.4p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Mediclinic International's is 0.8021. This would suggest that Mediclinic International's shares are less volatile than average (for this exchange).
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 hospitals, 2 day case clinics, 3 outpatient clinics, and 110 theatres with approximately 1,893 inpatient beds in Switzerland; 52 hospitals, 10 day case clinics, 8 sub-acute hospitals, and 305 theatres in South Africa and Namibia with approximately 8,792 inpatient beds; and 7 hospitals, 2 day case clinics, 18 outpatient clinics, and 38 theatres with approximately 927 inpatient beds in the United Arab Emirates. The company also provides treasury, hospital equipment and procurement, emergency medical, management, food and catering, healthcare management, and debt collection and related services; manages healthcare staff; and owns and manages properties. In addition, it engages in intellectual property holding and medical store/procurement businesses. The company was founded in 1983 and is based in Stellenbosch, South Africa.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.